HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 28 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $88,000 | – | 132,476 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 4,758,426 | $3,340,000 | 2.33% |
| PERKINS CAPITAL MANAGEMENT INC | 2,527,000 | $1,774,000 | 1.59% |
| Cowen Prime Services LLC | 2,137,900 | $1,501,000 | 0.69% |
| HighMark Wealth Management LLC | 192,000 | $134,000 | 0.14% |
| Nantahala Capital Management | 5,000,000 | $3,510,000 | 0.11% |
| Kalos Management, Inc. | 66,900 | $48,000 | 0.02% |
| FNY Investment Advisers, LLC | 20,500 | $14,000 | 0.00% |
| Virtu Financial LLC | 31,991 | $22,000 | 0.00% |
| Engineers Gate Manager LP | 25,440 | $18,000 | 0.00% |
| BlackRock Inc. | 405,725 | $285,000 | 0.00% |